| Placental growth factor, soluble fms-like tyrosine kinase 1, soluble endoglin, IL-6, and IL-16 as biomarkers in preeclampsia C Rădulescu, A Bacârea, A Huțanu, R Gabor, M Dobreanu Mediators of inflammation 2016, 2016 | 48 | 2016 |
| Serum levels of IL-17A in patients with relapsing–remitting multiple sclerosis treated with interferon-β R Bălaşa, Z Bajko, A Huţanu Multiple sclerosis journal 19 (7), 885-890, 2013 | 44 | 2013 |
| Serum leptin and leptin resistance correlations with NAFLD in patients with type 2 diabetes S Cernea, AL Roiban, E Both, A Huţanu Diabetes/metabolism research and reviews 34 (8), e3050, 2018 | 43 | 2018 |
| The adipokines and inflammatory status in the era of pediatric obesity SM Mărginean Oana, Meliț Lorena Elena, Huțanu Adina, Gliga D Cytokine 126, 154925, 2020 | 40 | 2020 |
| Predicting functional outcome of ischemic stroke patients in Romania based on plasma CRP, sTNFR-1, D-Dimers, NGAL and NSE measured using a biochip array A Huţanu, M Iancu, R Bălaşa, S Maier, M Dobreanu Acta pharmacologica sinica 39 (7), 1228-1236, 2018 | 38 | 2018 |
| An evaluation of serum procalcitonin and C-reactive protein levels as diagnostic and prognostic biomarkers of severe sepsis J Szederjesi, E Almasy, A Lazar, A Huțanu, I Badea, A Georgescu The Journal of Critical Care Medicine 1 (4), 147-153, 2015 | 32 | 2015 |
| Evaluation of TNF-α genetic polymorphisms as predictors for sepsis susceptibility and progression AM Georgescu, C Banescu, R Azamfirei, A Hutanu, V Moldovan, I Badea, ... BMC infectious diseases 20, 1-11, 2020 | 29 | 2020 |
| Ischemic damage and early inflammatory infiltration are different in the core and penumbra lesions of rat brain after transient focal cerebral ischemia E Horváth, A Huțanu, L Chiriac, M Dobreanu, A Orădan, EE Nagy Journal of Neuroimmunology 324, 35-42, 2018 | 25 | 2018 |
| Natalizumab changes the peripheral profile of the Th17 panel in MS patients: new mechanisms of action RI Balasa, M Simu, S Voidazan, LI Barcutean, Z Bajko, A Hutanu, I Simu, ... CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2017 | 20 | 2017 |
| Assessment of interleukin-17A, interleukin-10 and transforming growth factor-beta1 serum titers in relapsing remitting multiple sclerosis patients treated with avonex, possible … R Balasa, S Maier, S Voidazan, A Hutanu, Z Bajko, A Motataianu, B Tilea, ... CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2017 | 18 | 2017 |
| Vaccinium Extracts as Modulators in Experimental Type 1 Diabetes R Ştefănescu, C Vari, S Imre, A Huţanu, E Fogarasi, T Todea, A Groşan, ... Journal of medicinal food 21 (11), 1106-1112, 2018 | 16 | 2018 |
| Soluble urokinase-type plasminogen activator receptor (suPAR)–a possible biomarker for bacteremia in sepsis/Forma solubilă a receptorului pentru activatorul de plasminogen de … AM Georgescu, J Szederjesi, S Voidăzan, M Dobreanu, SM Copotoiu, ... Revista Romana De Medicina De Laborator 23 (1), 59-73, 2015 | 16 | 2015 |
| The matrix metalloproteinases panel in multiple sclerosis patients treated with natalizumab: a possible answer to natalizumab non-responders R Balasa, C Bianca, V Septimiu, S Iunius, H Adina, A Sebastian, ... CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2018 | 15 | 2018 |
| IL-6 gene polymorphisms and sepsis in ICU adult romanian patients: a prospective study AM Georgescu, C Bănescu, I Badea, V Moldovan, A Huțanu, S Voidăzan, ... Revista Romana de Medicina de Laborator 25 (1), 75-89, 2017 | 15 | 2017 |
| Correlations of serum leptin and leptin resistance with depression and anxiety in patients with type 2 diabetes S Cernea, E Both, A Huţanu, FL Şular, AL Roiban Psychiatry and Clinical Neurosciences 73 (12), 745-753, 2019 | 14 | 2019 |
| Plasma biomarkers as potential predictors of functional dependence in daily life activities after ischemic stroke: A single center study A Huțanu, M Iancu, S Maier, R Bălaşa, M Dobreanu Annals of Indian Academy of Neurology 23 (4), 496, 2020 | 12 | 2020 |
| Does the serum IL-17 titer influence the efficacy of interferon-β treatment in multiple sclerosis patients? R Bălaşa, A Huţanu, Z Bajko, C Feier, I Pascu Revista Română de Medicină de Laborator Vol 19 (4/4), 2011 | 12 | 2011 |
| The influence of Visfatin, RBP-4 and insulin resistance on bone mineral density in women with treated primary osteoporosis RMP Gabriea Mihai, Andrea Ildiko Gasparik, Ionela Maria Pascanu, Mariana ... Aging Clinical and Experimental Research, 2019 | 11 | 2019 |
| Clinical and serological biomarkers of treatment's response in multiple sclerosis patients treated continuously with interferonβ-1b for more than a decade LI Bărcuţean, A Romaniuc, S Maier, Z Bajko, A Moţăţăianu, H Adina, ... CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2018 | 11 | 2018 |
| Tribulus terrestris Efficacy and Safety Concerns in Diabetes and Erectile Dysfunction, Assessed in an Experimental Model R Ștefănescu, L Farczadi, A Huțanu, EB Ősz, M Mărușteri, A Negroiu, ... Plants 10 (4), 744, 2021 | 10 | 2021 |
Minodora DobreanuUniversitatea de Medicina, Farmacie, Stiinte si Tehnologie George Emil Palade din Tirgu Mures在 umfst.ro 的电子邮件经过验证
